Cerevel Therapeutics Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cerevel Therapeutics Holdings wird ein Gewinn- und Umsatzwachstum von 13.6% bzw. 70.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 17.8% pro Jahr wachsen soll.

Wichtige Informationen

16.4%

Wachstumsrate der Gewinne

21.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	69.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease

Oct 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CERE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	67	-562	-488	-453	4
12/31/2025	N/A	-561	-514	-534	6
12/31/2024	N/A	-472	-330	-436	8
3/31/2024	N/A	-460	-371	-367	N/A
12/31/2023	N/A	-433	-346	-342	N/A
9/30/2023	N/A	-393	-336	-332	N/A
6/30/2023	N/A	-397	-343	-340	N/A
3/31/2023	N/A	-388	-323	-320	N/A
12/31/2022	N/A	-352	-297	-293	N/A
9/30/2022	N/A	-318	-263	-258	N/A
6/30/2022	N/A	-280	-227	-222	N/A
3/31/2022	N/A	-243	-218	-210	N/A
12/31/2021	N/A	-225	-189	-179	N/A
9/30/2021	N/A	-196	-184	-168	N/A
6/30/2021	N/A	-173	-167	-144	N/A
3/31/2021	N/A	-146	-146	-125	N/A
12/31/2020	N/A	-148	-137	-118	N/A
9/30/2020	N/A	-175	-124	-112	N/A
6/30/2020	N/A	-172	-116	-111	N/A
3/31/2020	N/A	-151	-97	-94	N/A
12/31/2019	N/A	-128	-72	-71	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CERE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CERE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CERE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CERE wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CERE wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CERE in 3 Jahren voraussichtlich hoch sein wird

Cerevel Therapeutics Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.7% to US$36.60

Price target decreased by 8.1% to US$34.13

Price target decreased by 7.4% to US$34.38

Price target decreased by 8.8% to US$35.20

Price target decreased by 9.3% to US$37.09

Price target increased to US$43.29

Recent updates

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Price target increased by 9.7% to US$36.60

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

Independent Director notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Shareholder dilution

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Executive Chairman notifies of intention to sell stock

President recently bought US$2.0m worth of stock

Price target decreased by 8.1% to US$34.13

Price target decreased by 7.4% to US$34.38

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2023 Results on Aug 02, 2023

High number of new directors

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer, Effective from June 20, 2023

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Appoints Susan Altschuller as Chief Financial Officer

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. Announces Executive Changes

Price target decreased by 8.8% to US$35.20

Executive Chairman & CEO notifies of intention to sell stock

Price target decreased by 9.3% to US$37.09

Executive Chairman & CEO notifies of intention to sell stock

Executive Chairman & CEO exercised options and sold US$1.5m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Executive Chairman & CEO exercised options and sold US$1.3m worth of stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Executive Chairman & CEO exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Price target increased to US$43.29

President exercised options and sold US$371k worth of stock

President exercised options and sold US$186k worth of stock

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $253.75 million.

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

President notifies of intention to sell stock

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Price target decreased to US$39.71

Cerevel Therapeutics Appoints Suneet Varma to Serve as Member of Its Board of Directors

Chief Scientific Officer exercised options and sold US$1.4m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 10, 2022

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$895k worth of stock

Chief Scientific Officer exercised options and sold US$663k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Price target increased to US$46.33

Price target decreased to US$32.67

Price target increased to US$36.33

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Cerevel Therapeutics Holdings, Inc. Announces Positive Topline Results for Cvl-231 in Phase 1B Clinical Trial in Patients with Schizophrenia